Melatonin's Heart Health Breakthrough: What the Latest Trials Reveal

In a promising development for heart failure management, the MeHR trial—a randomized clinical trial—has found that nightly melatonin supplementation leads to meaningful improvements in how patients feel and function. Over 24 weeks, participants with stable heart failure with reduced ejection fraction (HFrEF) who took 10 mg of melatonin reported fewer disease exacerbations and a better overall clinical status. While mortality didn’t change, the composite clinical outcome score improved significantly, driven by real-world benefits like fewer hospitalizations and enhanced daily living.

This suggests melatonin may act beyond sleep regulation, potentially influencing inflammation, oxidative stress, and neurohormonal pathways involved in heart failure progression. The improvement in clinical trajectory without affecting hard cardiac structure points to a symptomatic and protective role rather than a curative one.

For patients managing chronic heart failure, this could mean a safe, accessible adjunct therapy that enhances well-being and reduces disease burden. However, this was a targeted population—those with stable HFrEF—and results don’t support broad use in other cardiac conditions yet.

Key implications:

• Melatonin may reduce heart failure flare-ups
• Benefits are most evident in symptom control and quality of life
• Not a replacement for standard heart failure therapies

One of the most striking findings from the MeHR trial was the dramatic improvement in New York Heart Association (NYHA) functional class among heart failure patients taking melatonin. After 24 weeks of 10 mg nightly supplementation, patients were 12.9 times more likely to improve by at least one functional class compared to those on placebo. This means many went from being limited by shortness of breath during light activity to being able to perform daily tasks more comfortably.

NYHA class is a powerful predictor of prognosis and daily functioning. Such a large shift suggests melatonin may help reduce symptom burden and increase physical tolerance, even if it doesn’t reverse heart damage. The mechanism may involve improved endothelial function, reduced oxidative stress, or better autonomic regulation during sleep.

While the odds ratio is impressive, it’s important to note this was seen in a controlled trial with stable patients already on optimal medical therapy. It doesn’t mean melatonin will work the same in advanced or untreated cases. Still, for clinicians and patients, this offers a compelling reason to consider melatonin as part of a holistic heart failure plan—especially for those struggling with sleep and fatigue.

The MeHR trial also revealed that melatonin has a measurable impact on cardiac biochemistry. Patients with stable heart failure who took 10 mg of melatonin nightly for 24 weeks experienced a mean reduction of 111 ng/L in serum NT-proBNP levels compared to placebo. NT-proBNP is a hormone released by the heart in response to strain, and higher levels correlate with worse heart failure severity and prognosis.

This reduction suggests melatonin may help ease the neurohormonal burden on the heart, possibly through anti-inflammatory and antioxidant effects. Unlike some heart failure drugs that target neurohormonal systems directly (like ACE inhibitors or beta-blockers), melatonin appears to modulate these pathways more gently—yet effectively enough to show a statistically and clinically meaningful change.

While the drop in NT-proBNP didn’t translate to structural improvements (like better ejection fraction), it still signals a healthier cardiac environment. For doctors, this could serve as a useful biomarker to monitor response to adjunct therapies. For patients, it reinforces that melatonin may be doing more than just helping them sleep—it might be helping their heart cope.

Beyond lab values and clinical scores, one of the most patient-centered findings from the MeHR trial is the improvement in quality of life. Participants taking melatonin reported a mean improvement of 5.8 points on the Minnesota Living with Heart Failure Questionnaire (MLHFQ)—a validated tool that measures how much heart failure affects physical and emotional well-being.

A 5-point change is considered clinically meaningful, meaning patients genuinely felt better. They reported less fatigue, improved mood, and greater ability to engage in daily activities. This is especially important in chronic heart failure, where quality of life often declines despite medical treatment.

Melatonin’s dual role in regulating sleep and reducing oxidative stress may explain these benefits. Poor sleep is common in heart failure and can worsen symptoms. By improving sleep quality and potentially reducing nighttime cardiac stress, melatonin may create a positive feedback loop that enhances overall well-being.

While not a cure, this level of symptomatic relief is valuable—and achievable with a low-risk supplement.

Despite its benefits on symptoms and biomarkers, melatonin does not appear to reverse the structural changes of heart failure. The MeHR trial found no significant changes in left ventricular ejection fraction (LVEF) or left ventricular end-diastolic diameter (LVEDD) after 24 weeks of 10 mg nightly supplementation. This means the heart’s pumping ability and chamber size remained unchanged compared to placebo.

This is a crucial distinction: melatonin improves how patients feel and function, but it doesn’t repair the damaged heart muscle. It should not be viewed as a substitute for guideline-directed medical therapies like beta-blockers, ACE inhibitors, or SGLT2 inhibitors, which have been shown to improve survival and reverse remodeling.

However, the lack of structural change doesn’t diminish melatonin’s value. Many effective therapies—like diuretics or digoxin—also improve symptoms without altering heart structure. Melatonin may belong in that category: a supportive, symptom-focused adjunct that enhances comfort and stability without replacing foundational treatments.

With millions using over-the-counter melatonin for sleep, concerns have grown about its long-term cardiovascular safety. Two observational studies (both scoring 59/100) explored whether chronic melatonin use in adults with insomnia increases the risk of developing heart failure. While not definitive, the data suggest no significant increase in heart failure incidence or mortality among long-term users.

These findings are reassuring, especially given melatonin’s widespread use. However, the studies were not randomized trials and had moderate methodological limitations—such as potential confounding by sleep quality, lifestyle factors, or underlying health conditions. Still, the absence of a clear signal of harm is encouraging.

The research doesn’t prove melatonin is protective, nor does it support using it specifically for heart health in healthy individuals. But for people with chronic insomnia who rely on melatonin, these results suggest it may be a relatively safe option from a cardiovascular standpoint—especially when used as directed.